Viktoriia Moskvina

EDUCATION

BS/MS of Science in Chemistry, Taras Shevchenko National University of Kyiv, 2001-2006
PhD, Taras Shevchenko National University of Kyiv, 2009

RESEARCH INTERESTS

heterocycles

Scopus Publications

Synthesis of Enantioenriched 2-((Hetera)Cyclo) Alkylchromanols and their Spirocyclic Analogs through Enzymatic Resolution
Oleksii S. Timokhin, Anastasiia M. Romanova, Viktoria S. Moskvina, Olexandr V. Kucher, Aleksandr I. Boiko, Anna L. Banasevych, Dmytro Durylin, Volodymyr S. Brovarets, and Oleksandr O. Grygorenko
Wiley
AbstractAn efficient approach to the multigram synthesis of 2‐((hetera) cyclo) alkylchromanols and their spirocyclic analogs based on enzymatic resolution is described. It is shown that enzymatic acylation could be used for the preparation of enantioenriched title compounds with primary alkyl substituents at the C‐2 position. Meanwhile, enzymatic hydrolysis of the corresponding acetates was optimal for the preparation of the target alcohols when significant steric hindrance is present, e. g., due to the α‐branching. The latter factor was demonstrated to be crucial for the enzymatic reaction rate in both cases. The synthetic utility of the obtained chiral alcohols was demonstrated through Mitsunobu configuration inversion, as well as by preparation of the corresponding primary amines – valuable sp3‐enriched building blocks for medicinal chemistry.


Progress in the synthesis of 3-fluorochromones (microreview)
Yelyzaveta Y. Rybina and Viktoriia S. Moskvina
Springer Science and Business Media LLC



Modified Neoflavones Based on 7-Hydroxyneoflavone-6-Enamino Ketone and 7-Hydroxy-3-Hetarylbenzopyran-2- and 4-Ones Mannich Bases and Their Recyclization
E. K. Hlibov, N. V. Gorbulenko, V. S. Moskvina, O. V. Shablykina, T. V. Shokol, A. V. Kozytskyi, and V. P. Khilya
Springer Science and Business Media LLC



Synthesis and in vitro anticancer evaluation of functionalized 5-(4-piperazin-1-yl)-2-aryloxazoles and 5-[(4-arylsulfonyl)piperazin-1-yl]-2-phenyloxazoles
Oleksandr O. Severin, Stepan G. Pilyo, Viktoriia S. Moskvina, Olga V. Shablykina, Yevgen A. Karpichev, and Volodymyr S. Brovarets
Springer Science and Business Media LLC



ENERGY METABOLISM IN THE LIVER OF RATS WITH ROTENONE-INDUCED PARKINSONIAN SYNDROME UNDER THE INFLUENCE OF METHANINDIAZENONЕ
, L.Ya. Shtanova, S.P. Veselsky, , P.I. Yanchuk, , O.V. Tsymbalyuk, , V.S. Moskvina, ,et al.
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Parkinson’s disease (PD) is symptomatically characterized by motor disorders in the human body, which are associated with the degeneration of dopamine neurons in the substantia nigra of the midbrain. It is widely recognized that mitochondrial dysfunction occurs in dopaminergic neurons, leading to their death and the development of this pathology. Recently, benzodiazepine derivatives have been found to have a neuroprotective effect against damage of dopaminergic neurons in an experimental model of Рarkinsonian syndrome (PS). The aim of this study was to investigate the effect of a novel molecule, named methanіdiazenone, on energy metabolism in the liver of rats induced by rotenone. To achieve the set goal, the concentration of ATP, ADP, AMP, hypoxanthine аnd xanthine were determined in the bile samples of rats with PS by the method of thin-layer chromatography. The obtained data indicate that under the influence of rotenone compared to the control values the content of ATP in bile decreased by 40%, while the levels of AMP, xanthine and hypoxanthine, on the contrary, increased by 87,5%, 55,6%, and 25%, respectively. Our findings suggested that the ratio of AMP/ATP, which is an important indicator of the functional state of mitochondria, under the influence of rotenone increased by 200% compared to the control. Metanindiazenone in a dose of 1,0 and 2,0 mg/kg normalized all studied parameters of purine metabolism. The presented results show that methanindiazenone significantly improves purine metabolism in the liver of rats with PS induced by rotenone, indicating the normalization of mitochondrial function in hepatocytes. Thus, methanindiazenone may be recommended for clinical trials regarding its use in combination with other drugs to treat Parkinson’s disease and possibly other neurodegenerative diseases, in which mitochondrial dysfunction occurs.


Distinctive Features of 3-Acetyl- and 3-Benzoyl-Isocoumarins’ Interaction with Active Primary Amines
Artem S. Konovalenko, Oleh V. Shablykin, Olga V. Shablykina, Viktoriia S. Moskvina, Svitlana V. Shishkina, Andrii V. Kozytskiy, and Volodymyr S. Brovarets
Wiley
AbstractIsoquinolones and isoquinolines are crucial natural and synthetic heterocyclic compounds exhibiting a range of biological activities. A less explored strategy for the recyclization of isocoumarins to isoquinolones involves the transformation of 1H‐isochromen‐1‐ones with a carbonyl group at position 3 using primary amines. This study presents a straightforward one‐pot protocol for the recyclization of 3‐acetyl‐ and 3‐benzoylisocoumarins into their corresponding isoquinolone derivatives using structurally diverse primary amines. This provides versatile and scalable routes for accessing a variety of 2‐R‐isoquinolin‐1(2H)‐ones. Interestingly, the acyl group also reacted with the hydroxyl group of 2‐aminoethanol, leading to the simultaneous formation of 3,4‐dihydro[1,4]oxazino[4,3‐b]isoquinolin‐6(1H)‐ones alongside lactone recyclization. Moreover, the recyclization process was accompanied by more complex alternative cyclizations, including an oxidative‐reductive stage. For instance, the recyclization of isocoumarins with benzylamine resulted in the formation of isochromeno[3,4‐c]pyrroles, whereas with glycine derivatives, 1,2‐dihydro‐6H‐pyrazino[1,2‐b]isoquinolin‐3,6(4H)‐diones were obtained.


Unexpected but prominent imines formation in Beckmann rearrangement of (spiro)pyranocoumarin oximes
Igor V. Krasylov, Viktoriia S. Moskvina, and Volodymyr P. Khilya
Elsevier BV



Parent 5(7)-azachromones and their partially hydrogenated derivatives: synthesis and physicochemical properties
Yehor S. Malets, Bohdan V. Vashchenko, Viktoriia S. Moskvina, Oleksandr V. Golovchenko, Volodymyr S. Brovarets, and Oleksandr O. Grygorenko
Springer Science and Business Media LLC



Expanding the isoflavone, pyrazole, and oxazole chemical space through 2'-carboxamido-2-hydroxydeoxybenzoin precursors
Kateryna V. Kukushkina, Viktoriia S. Moskvina, Olga V. Shablykina, and Volodymyr P. Khilya
Springer Science and Business Media LLC



Straightforward trifluoroacylation of oxazoles – scalable, cost-effective way toward diverse 2-(trifluoroacetyl)oxazoles
Vladyslav S. Savchenko, Oleksandr V. Geraschenko, Pavlo V. Khodakivskyi, Tetiana V. Druzhenko, Viktoria S. Moskvina, Sergey V. Ryabukhin, and Dmitriy M. Volochnyuk
Springer Science and Business Media LLC



3-Fluoroalkyl (CF<inf>3</inf>, CHF<inf>2</inf>, CH<inf>2</inf>F) Cyclobutane-Derived Building Blocks for Medicinal Chemistry: Synthesis and Physicochemical Properties
Oleksandr P. Demchuk, Bohdan V. Bobovskyi, Bohdan V. Vashchenko, Oleksandr V. Hryshchuk, Artem Skreminskyi, Anton V. Chernykh, Viktoriia S. Moskvina, Olga V. Hordiyenko, Dmitriy M. Volochnyuk, and Oleksandr O. Grygorenko
Wiley



Expanding the Chemical Space of 1,2-Difunctionalized Cyclobutanes
Anton V. Chernykh, Oleksandr V. Kudryk, Oleksandr S. Olifir, Alexey V. Dobrydnev, Eduard Rusanov, Viktoriia S. Moskvina, Dmitriy M. Volochnyuk, and Oleksandr O. Grygorenko
American Chemical Society (ACS)
An efficient approach to the synthesis of previously unavailable or hardly accessible 1,2-difunctionalized cyclobutanes (mostly with NH2/NHBoc, OH, SH, or SO2F groups attached to the carbocycle either directly or via a CH2 unit) relying on the divergent strategy is described. This class of compounds provides sp3-enriched and conformationally restricted building blocks that are of special demand for medicinal chemistry. The target compounds were prepared not only as pure racemic (±)-cis- and (±)-trans-diastereomers but in some cases also as single enantiomers. The developed procedures are readily scaled up and allow obtaining the target compounds on an up to hundred-gram scale. On the basis of the results of 20 X-ray diffraction experiments, structural characterization of the 1,2-difunctionalized cyclobutane core was performed using the extended Cremer-Pople puckering parameters and exit vector (EVP) plots.


Benzodiazepinе derivative methanindiazenone modulates lipid metabolism in the liver of rats with rotenone-induced Parkinson’s syndrome
L.Ya. Shtanova, , S.P. Vesеlsky, P.I. Yanchuk, O.V. Tsymbalyuk, O.F. Moroz, E.M. Reshetnik, V.S. Moskvina, O.V. Shablykina, О.V. Kravchenko,et al.
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Parkinson’s disease (PD) is a neurodegenerative condition for which the exact causes remain elusive, and no effective treatments currently exist. The pathogenesis of PD is believed to involve oxidative stress, mitochondrial dysfunction, and lipid metabolism disorders. A benzodiazepine derivative JM-20 has demonstrated protective effects on mitochondria in both neurons and peripheral tissues of rats with rotenoneinduced Parkinson’s syndrome (PS). This study aimed to analyze bile composition and assess the impact of a new benzodiazepine derivative, methanindiazenone, on lipid metabolism in the liver of rats subjected to the rotenone model of PS. The results indicated that, compared to the control group, bile concentration of phospholipids, cholesterol, cholesterol esters, and triglycerides decreased by 24.3, 26.2, 25.8, and 27.5%, respectively. With methanindiazenone treatment at doses of 0.5 and 1.0 mg/kg, all these metrics reverted to the control level. However, in the rotenone+methanindiazenone 2.0 mg/kg group, the levels of phospholipids, cholesterol, and cholesterol esters (except for triglycerides) surpassed the control values by 33, 28.1, 28.4 and 33.5%, respectively. Methanindiazenone positively impacted the motor behavior of rats with the rotenone model of PS and enhanced their survival rates. Therefore, at doses of 0.5 and 1.0 mg/kg, methanindiazenone not only improved lipid metabolism in the liver but also the overall well-being of rats with the rotenone model of PS. However, a 2 mg/kg dose of methanindiazenone displayed toxic effects, as seen from the increased content of phospholipids, cholesterol, and cholesterol esters in bile. Hence, methanindiazenone holds potential as a therapeutic agent for PS and possibly other neurodegenerative diseases related to lipid metabolism impairment, but its use should be limited to doses of 0.5 and 1.0 mg/kg.


Synthesis and Recyclization of Methylenebisflavonoids Based on Heterocyclic Analogs of Umbelliferone and Formononetin
E. K. Glibov, N. V. Gorbulenko, V. S. Moskvina, A. V. Suprun, O. V. Shablykina, T. V. Shokol, and V. P. Khilya
Springer Science and Business Media LLC



Rapid synthetic approaches to libraries of diversified 1,2-dihydrochromeno[2,3-c]pyrrole-3,9-diones and 3-(2-hydroxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-ones
Roman N. Vydzhak, Svitlana Ya. Panchishin, Maryna V. Kachaeva, Stepan G. Pilyo, Viktoriia S. Moskvina, Olga V. Shablykina, Andriy V. Kozytskiy, and Volodymyr S. Brovarets
Springer Science and Business Media LLC
Graphic abstract An efficient and practical synthetic procedure for libraries of diversified 1,2-dihydrochromeno[2,3-c]pyrrole-3,9-diones using a multicomponent process is presented. A convenient synthetic procedure for obtaining functionalized 3-(2-hydroxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-ones via ring-opening strategy has also been developed. This protocol was found to be compatible with a wide range of substituents and paves the way for the practical synthesis of title compounds with a broad range of substituents under mild condition. The products can be easily isolated by crystallization without the use of chromatography. Supplementary Information The online version contains supplementary material available at 10.1007/s11030-021-10234-2.


Synthesis of saturated and partially saturated heterocyclic boronic derivatives
Oleksandr O. Grygorenko, Viktoriya S. Moskvina, Ihor Kleban, and Oleksandr V. Hryshchyk
Elsevier BV



1H-isochromene-1-ones and isoquinoline-1(2H)-ones with carbonyl group in position 3: Features of synthetic approaches and transformation
Artem S. Konovalenko, Olga V. Shablykina, Oleh V. Shablykin, Viktoriia S. Moskvina, and Volodymyr S. Brovarets
ARKAT USA, Inc.



Purine and lipid metabolism in rats with a rotenone model of Parkinson’s disease under the influence of methanindiazenone
L.Ya. Shtanova, , S.P. Vesеlsky, P.I. Yanchuk, O.V. Tsymbalyuk, V.S. Moskvina, O.V. Shablykina, O.F. Moroz, T.V. Vovkun, О.V. Kravchenko,et al.
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
This study aims to evaluate the effect of methanindiazenone (МD), a new benzodiazepine derivative, on the levels of purine metabolites and lipids in the blood plasma of rats with rotenone (ROT) induced Parkinson’s disease (PD). The concentrations of ATP, ADP, AMP, xanthine, hypoxanthine, phospholipids (PL), cholesterol (CHOL), cholesterol esters (ECHOL), free fatty acids (FFA), and triglycerides (TG) were quantified in plasma samples by thin-layer chromatography. Our data demonstrate that in rats with ROT-induced PD the AMP/ATP ratio in plasma increased by 2.5 times compared to the control, and this indicator returned to normal values under the influence of MD. ROT also increased the concentration of xanthine and hypoxanthine by 26.7% (Р &lt; 0.001) and 42.4% (Р &lt; 0.001), respectively, compared to the control. MD restored xanthine concentration to 86.7% of the control level and returned hypoxanthine concentration to normal values. Besides, ROT reduced the blood plasma concentrations of PL, CHOL, ECHOL, FFA, TG by 22%, (Р &lt; 0.001), 18% (Р &lt; 0.001), 25% (Р &lt; 0.001), 28% (Р &lt; 0.001), 33% (Р &lt; 0.001), respectively. Under the influence of MD, such indicators as the blood plasma concentration of PL, CHOL, FFA returned to control levels. Оur results suggest that MD improves the metabolism of both purines and lipids in rats with ROT-induced PD.


Bicyclic 6-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: Three Extra Heteroatoms (2:1)
Oleksandr O. Grygorenko, Valeriia Hutskalova, and Victoriia S. Moskvina
Elsevier



The effect of heterocyclic substituent at C-3 position of 1-(4-methyl-piperazin-1-yl)isoquinolines on their anticancer activity
A. S. Konovalenko, V. V. Zhirnov, O. V. Shablykin, O. V. Shablykina, V. S. Moskvina, and V. S. Brovarets
Institute of Molecular Biology and Genetics (NAS Ukraine)
Aim. A comparative analysis of the anti-cancer activity of 1-(4-methylpiperazin-1-yl)isoqui-nolines with different heteroaromatic substituents in С-3 position: 2-methylthiazol-4-yl, 2-phenylthiazol-4-yl, 2-(pyridin-4-yl)thiazol-4-yl, imidazo[2,1- b ]thiazol-6-yl, quinoxalin-2-yl, 6,7-dimethylquinoxalin-2-yl. Methods. Biological tests; statistic methods. Results. In vitro screening of the anticancer activity showed that the derivatives with 2-phenylthiazol-4-yl, quinoxaline-2-yl, 6,7-dimethylquinoxalin-2-yl substituents demonstrated the highest level of anticancer activity; however, they were inferior to 2-(pyridin-4-yl)thiazol-4-yl. The product with the 2-methylthiazol-4-yl residue almost did not demonstrated cytotoxicity. Comparative analysis showed no significant correlation with known drugs; hence these compounds have specific molecular targets. Conclusions. The resulting 1-amino-3-hetarylisoquinolines are a promising class of compounds for anticancer drug development. The level and direction of the activity significantly depend on the nature of heterocyclic substituents.


Concise and regioselective synthesis of 5H-imidazo[1,2-e][1,3,5]triazepines
Viktoriia Moskvina, Bohdan Demydchuk, Oleksandr Mykhalchenko, Eduard Rusanov, and Volodymyr Brovarets
ARKAT USA, Inc.



Functionalized 5-Amino-4-cyanoxazoles, their Hetero- and Macrocyclic Derivatives: Preparation and Synthetic Applications
Danylo O. Merzhyievskyi, Oleh V. Shablykin, Olga V. Shablykina, Andriy V. Kozytskiy, Eduard B. Rusanov, Viktoriia S. Moskvina, and Volodymyr S. Brovarets
Wiley



Corrective effects of benzodiazepine derivative – diazepinone on purine and lipid metabolism in the liver of rats with parkinson’s disease
l.Ya. Shtanova, , P.I. Yanchuk, S.P. Vesеlsky, O.V. Tsymbalyuk, T.V. Vovkun, V.S. Moskvina, O.V. Shablykina, A.A. Kravchenko, V.N. Baban,et al.
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The cause of PD is not fully understood, and effective treatments still do not exist. It is believed that oxidative stress, mitochondrial dysfunction, and impaired lipid metabolism may underlie the pathogenesis of PD. Bile contains the breakdown products of various compounds that form in hepatocytes. This study aimed to evaluate the effect of a new benzodiazepine derivative - diazepinone (DP) on purine and lipid metabolism in the liver of rats with PD caused by rotenone (ROT) by studying the composition of bile. The concentration of ATP, ADP, AMP, xanthine, hypoxanthine, phospholipids (PL), cholesterol (CHOL), cholesterol esters (ECHOL), free fatty acids (FFA), and triglycerides (TG) was quantified in bile samples by thin-layer chromatography. Our findings suggested that the ratio of AMP/ ATP in bile increased almost threefold under the influence of ROT, and with DP, it exceeded the norm by only 1.6 times. ROT also increased the content of xanthine and hypoxanthine by 28.6% and 66.7%, respectively. DP did not affect the increased xanthine content relative to control but significantly reduced the level of hypoxanthine (up to 22.2%, above normal). In addition, ROT reduced the content of bile PL, CHOL, ECHOL, TG by 23.9%, 38.6%, 47.5%, 39.2 %, respectively. Under the influence of the DP, all the above indicators returned to the level of control. Thus, diazepinone improves both the metabolism of purines and lipids in the liver of rats with ROT-simulated PD. This drug may become a therapeutic agent for treating PD and possibly other neurodegenerative diseases in the future.


Inhibition of hyaluronan secretion by novel coumarin compounds and chitin synthesis inhibitors
Alexandra A Tsitrina, Igor V Krasylov, Dmitry I Maltsev, Irina N Andreichenko, Viktoria S Moskvina, Dmitry N Ivankov, Elena V Bulgakova, Mikhail Nesterchuk, Vera Shashkovskaya, Nataliya O Dashenkova,et al.
Oxford University Press (OUP)
Abstract Elevated plasma levels of hyaluronic acid (HA) is a disease marker in liver pathology and other inflammatory disorders. Inhibition of HA synthesis with coumarin 4-methylumbelliferone (4MU) has a beneficial effect in animal models of fibrosis, inflammation, cancer and metabolic syndrome. 4MU is an active compound of approved choleretic drug hymecromone with low bioavailability and a broad spectrum of action. New, more specific and efficient inhibitors of hyaluronan synthases (HAS) are required. We have tested several newly synthesized coumarin compounds and commercial chitin synthesis inhibitors to inhibit HA production in cell culture assay. Coumarin derivative compound VII (10′-methyl-6′-phenyl-3′H-spiro[piperidine-4,2′-pyrano[3,2-g]chromene]-4′,8′-dione) demonstrated inhibition of HA secretion by NIH3T3 cells with the half-maximal inhibitory concentration (IC50) = 1.69 ± 0.75 μΜ superior to 4MU (IC50 = 8.68 ± 1.6 μΜ). Inhibitors of chitin synthesis, etoxazole, buprofezin, triflumuron, reduced HA deposition with IC50 of 4.21 ± 3.82 μΜ, 1.24 ± 0.87 μΜ and 1.48 ± 1.44 μΜ, respectively. Etoxazole reduced HA production and prevented collagen fibre formation in the CCl4 liver fibrosis model in mice similar to 4MU. Bioinformatics analysis revealed homology between chitin synthases and HAS enzymes, particularly in the pore-forming domain, containing the proposed site for etoxazole binding.


Progress in the Chemistry of Amino-Acid Derivatives of Isocoumarins and 3,4-Dihydroisocoumarins
O. V. Shablykina, S. V. Shilin, V. S. Moskvina, V. V. Ishchenko, and V. P. Khilya
Springer Science and Business Media LLC

RECENT SCHOLAR PUBLICATIONS

Progress in the synthesis of 3-fluorochromones (microreview)
YY Rybina, VS Moskvina
Chemistry of Heterocyclic Compounds, 1-3 2025



PROGRESS IN THE SYNTHESIS OF 3-FLUOROCHROMONES
YY Rybina, VS Moskvina
Chemistry of Heterocyclic Compounds 60 (9/10), 430-432 2024



Synthesis of Enantioenriched 2‐((Hetera) cyclo) alkylchromanols and their Spirocyclic Analogs through Enzymatic Resolution
OS Timokhin, AM Romanova, VS Moskvina, OV Kucher, AI Boiko, ...
European Journal of Organic Chemistry, e202401247 2024



Synthesis and in vitro anticancer evaluation of functionalized 5-(4-piperazin-1-yl)-2-aryloxazoles and 5-[(4-arylsulfonyl)piperazin-1-yl]-2-phenyloxazoles
OO Severin, SG Pilyo, VS Moskvina, OV Shablykina, YA Karpichev, ...
Chemistry of Heterocyclic Compounds, 1-7 2024



Modified Neoflavones Based on 7-Hydroxyneoflavone-6-Enamino Ketone and 7-Hydroxy-3-Hetarylbenzopyran-2-and 4-Ones Mannich Bases and Their Recyclization
EK Hlibov, NV Gorbulenko, VS Moskvina, OV Shablykina, TV Shokol, ...
Chemistry of Natural Compounds 60 (2), 223-228 2024



Exploring aminomethylcoumarins: versatile synthesis, structural diversity, and ADME prediction
EK Hlibov, VS Moskvina, YS Malets, VP Khilya
Ukrainica Bioorganica Acta 18 (2), 22-30 2023



Synthesis of chromeno[2,3-c]pyrrol-9(2H)-ones (microreview)
VS Moskvina, VP Khilya
Chemistry of Heterocyclic Compounds 59 (11), 736-738 2023



Distinctive Features of 3‐Acetyl‐and 3‐Benzoyl‐Isocoumarins’ Interaction with Active Primary Amines
AS Konovalenko, OV Shablykin, OV Shablykina, VS Moskvina, ...
ChemistrySelect 8 (37), e202301380 2023



Unexpected but prominent imines formation in Beckmann rearrangement of (spiro) pyranocoumarin oximes
IV Krasylov, VS Moskvina, VP Khilya
Tetrahedron Letters 129, 154747 2023



Функціоналізація оксимів (спіро) піранокумаринів
ІВ Красилов, ВС Москвіна, ВП Хиля
Доповіді Національної академії наук України, 52-59 2023



Parent 5 (7)-azachromones and their partially hydrogenated derivatives: synthesis and physicochemical properties
YS Malets, BV Vashchenko, VS Moskvina, OV Golovchenko, VS Brovarets, ...
Chemistry of Heterocyclic Compounds 59 (6), 494-499 2023



Straightforward trifluoroacylation of oxazoles–scalable, cost-effective way toward diverse 2-(trifluoroacetyl) oxazoles
VS Savchenko, OV Geraschenko, PV Khodakivskyi, TV Druzhenko, ...
Chemistry of Heterocyclic Compounds 59 (6), 472-478 2023



Expanding the isoflavone, pyrazole, and oxazole chemical space through 2'-carboxamido-2-hydroxydeoxybenzoin precursors
KV Kukushkina, VS Moskvina, OV Shablykina, VP Khilya
Chemistry of Heterocyclic Compounds 59 (6), 479-483 2023



Synthetic approach to spiropyranocoumarins and their oxime derivatives
IV Krasylov, VS Moskvina, VP Khilya
Ukrainica Bioorganica Acta 18 (1), 42-51 2023



Front Cover: 3‐Fluoroalkyl (CF₃, CHF₂, CH₂F) Cyclobutane‐Derived Building Blocks for Medicinal Chemistry: Synthesis and Physicochemical Properties (Eur. J
OP Demchuk, BV Bobovskyi, BV Vashchenko, OV Hryshchuk, ...
European Journal of Organic Chemistry 26 (24), e202300559 2023



3‐Fluoroalkyl (CF₃, CHF₂, CH₂F) Cyclobutane‐Derived Building Blocks for Medicinal Chemistry: Synthesis and Physicochemical Properties
OP Demchuk, BV Bobovskyi, BV Vashchenko, OV Hryshchuk, ...
European Journal of Organic Chemistry 26 (24), e202300292 2023



Expanding the chemical space of 1, 2-difunctionalized cyclobutanes
AV Chernykh, OV Kudryk, OS Olifir, AV Dobrydnev, E Rusanov, ...
The Journal of Organic Chemistry 88 (5), 3109-3131 2023



Benzodiazepinе derivative methanindiazenone modulates lipid metabolism in the liver of rats with rotenone-induced Parkinson’s syndrome
L Shtanova, S Vesеlsky, P Yanchuk, O Tsymbalyuk, O Moroz, E Reshetnik, ...
Фізіологічний журнал, 2023, Т. 69,№ 6 2023



The N-(2, 4-diarylthiazol-5-yl) benzamidines library creation and the effect of this compounds on cancer cell growth
OO Severin, MV Kachaeva, SG Pilyo, OV Shablykina, VS Moskvina, ...
Ukrainica Bioorganica Acta 17 (2), 14-22 2022



A combinatorial library of substituted 3-sulfonyl-2-imino-1, 2-dihydro-5H-dipyrido [1, 2-a: 2', 3'-d] pyrimidin-5-ones and their anticancer activities.
SG Pilyo, BA Demydchuk, VS Moskvina, OV Shablykina, VS Brovarets
Biopolymers & Cell 38 (4) 2022

MOST CITED SCHOLAR PUBLICATIONS

Cycloadditions of alkenylboronic derivatives
OO Grygorenko, VS Moskvina, OV Hryshchuk, AV Tymtsunik
Synthesis 52 (19), 2761-2780 2020
Citations: 23



Synthesis of pyrano[2,3-f]chromen-2,8-diones and pyrano[3,2-g]chromen-2,8-diones based on o-hydroxyformyl(acyl)neoflavonoids
VS Moskvina, VP Khilya
Chemistry of Natural Compounds 44, 16-23 2008
Citations: 17



A Versatile Synthesis of Heterocyclic Analogues of Neoflavonoids from Enamino Ketones
VS Moskvina, VP Khilya, OV Turov, UM Groth
Synthesis 2009 (08), 1279-1286 2009
Citations: 15



Expanding the chemical space of 1, 2-difunctionalized cyclobutanes
AV Chernykh, OV Kudryk, OS Olifir, AV Dobrydnev, E Rusanov, ...
The Journal of Organic Chemistry 88 (5), 3109-3131 2023
Citations: 12



Recent Progress in the Synthesis of 4-Arylcoumarins
VS Moskvina, VP Khilya
Chemistry of Natural Compounds 55, 401-427 2019
Citations: 12



2-(Dichloromethyl) pyrazolo [1, 5-a][1, 3, 5] triazines: synthesis and anticancer activity
YS Velihina, SG Pil’o, VS Zyabrev, VS Moskvina, OV Shablykina, ...
Biopolymers & Cell 36 (1), 60 2020
Citations: 11



Synthesis of azachromones and azachromanones
YS Malets, VS Moskvina, OO Grygorenko, VS Brovarets
Chemistry of Heterocyclic Compounds 55, 1007-1012 2019
Citations: 11



Aryl alkynoates in the radical synthesis of coumarins
VS Moskvina, VP Khilya
Chemistry of Heterocyclic Compounds 55, 300-306 2019
Citations: 11



3-Hetarylisocoumarins in the synthesis of 1-functionalized 3-hetarylisoquinolines
AS Konovalenko, OV Shablykin, VS Brovarets, OV Shablykina, ...
Chemistry of Heterocyclic Compounds 56, 1021-1029 2020
Citations: 10



Condensation of 2-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl) ethanone with N,N-dimethylformamide dimethyl acetal: an effective approach to 3-(4-chlorophenyl)-7-methoxy-4
VS Moskvina, SV Shilin, VP Khilya
Chemistry of Heterocyclic Compounds 51, 799-803 2015
Citations: 10



Inhibition of hyaluronan secretion by novel coumarin compounds and chitin synthesis inhibitors
AA Tsitrina, IV Krasylov, DI Maltsev, IN Andreichenko, VS Moskvina, ...
Glycobiology 31 (8), 959-974 2021
Citations: 9



Reactions of 3-arylisocoumarins with N-nucleophiles–a route to novel azaheterocycles
VS Moskvina, OV Shablykina, VP Khilya
Current Topics in Medicinal Chemistry 17 (29), 3199-3212 2017
Citations: 9



Synthesis and structure of 4-arylspirodihydro-pyranochromen-2-one derivatives
VS Moskvina, YL Garazd, MM Garazd, AV Turov, VP Khilya
Chemistry of Heterocyclic Compounds 43, 421-429 2007
Citations: 8



3‐Fluoroalkyl (CF₃, CHF₂, CH₂F) Cyclobutane‐Derived Building Blocks for Medicinal Chemistry: Synthesis and Physicochemical Properties
OP Demchuk, BV Bobovskyi, BV Vashchenko, OV Hryshchuk, ...
European Journal of Organic Chemistry 26 (24), e202300292 2023
Citations: 6



Pyranoneoflavonoids: Synthesis and structure
VS Moskvina, DY Masich, VP Khilya, VP Khilya
Dopov Nac akad nauk Ukr 12, 122-127 2014
Citations: 6



Functionalized 5‐Amino‐4‐cyanoxazoles, their Hetero‐and Macrocyclic Derivatives: Preparation and Synthetic Applications
DO Merzhyievskyi, OV Shablykin, OV Shablykina, AV Kozytskiy, ...
European Journal of Organic Chemistry 2021 (47), 6511-6523 2021
Citations: 5



8-(Methyl(phenyl)sulfonyl)-2,6-dihydroimidazo[1,2-c]- pyrimidin-5(3Н)-ones and 9-(methyl(phenyl)sulfonyl)- 2,3,4,7-dihydro-6H-pyrimido[1,6-a]pyrimidin-6-ones
RN Solomyannyi, OV Shablykina, VS Moskvina, VP Khilya, EB Rusanov, ...
Chemistry of Heterocyclic Compounds 55, 401-407 2019
Citations: 5



Anticancer activity of isoquinoline derivatives—products of 3-(2-(thien-2-yl) thiazol-4-yl isocoumarin recyclization
AS Konovalenko, OV Shablykin, OV Shablykina, VS Moskvina, ...
2019
Citations: 5



Efficient synthesis of 1-oxo-3-aryl-1H-isochromene-4-carbaldehydes from enaminoketones of 2′-carboxamidodeoxybenzoins
VS Moskvina, OV Shablykina, VV Ishchenko, VP Khilya
Tetrahedron Letters 58 (3), 245-247 2017
Citations: 5



Dop
VS Moskvina, OV Shablykina, OV Turov, VV Ishchenko, VP Khilya
NAN Ukraine, 144-149 2012
Citations: 5